DKTK/CCCC LECTURE Control of Normal and Malignant Stem Cell Activity: The many faces of MYC

Veranstaltung ausschließlich für Fachpublikum

Dear Colleagues,

It is our pleasure to cordially invite you to the Lecture of Prof. Andreas Trumpp (German Cancer Research Center (DKFZ) and Heidelberg Institute for Stem Cell Technology and Experimental Medicine).
   

DKTK/CCCC Lecture
Control of Normal and Malignant Stem Cell Activity: The many faces of MYC
Andreas Trumpp, PhD
Professor and Head of the Division "Stem Cells and Cancer", German Cancer Research Center (DKFZ)
Managing Director of the "Heidelberg Institute for Stem Cell Technology and Experimental Medicine" (HI-STEM gGmbH)

 
Date:                    September 22, 2016
Time:                    3 -4 pm
Venue:                 Charité – Universitätsmedizin
Institute of Pathology
Campus Charité Mitte
Lecture Hall Pathology
Virchowweg 15
10117 Berlin
 
 
 

Abstract: Over the last 15 years the Trumpp team has contributed to a better understanding of the molecular and cellular basis of normal and malignant stem cell self-renewal and differentiation. For example, they demonstrated that the most potent hematopoietic stem cells (HSC) are in a state of deep dormancy during homeostasis and that stress signals (chemotherapy) or bacterial/viral infections cannot only activate these HSCs to produce new stem cells and progenitors, but make them also exquisitely sensitive to chemotherapy induced killing (Nature 2001, Cell 2008; Nature 2009; Nature Reviews Immunology 2010; Cell Stem Cell 2014; Nature 2015). His group also demonstrated that the MYC oncogene controls entry and exit of the dormancy state in HSCs and pluripotent cells in pre-implantation embryos (GenesDev. 2004; Cell 2016). In addition to a MDS and leukemic stem cell program (Cell Stem Cell 2014), the team has identified circulating metastasis stem cells in the blood of breast cancer patients, which offer novel possibilities for the design of better diagnostic and therapeutic tools for metastatic breast cancer (Nature Biotechnology 2013, Oncotarget 2014). In pancreatic cancer his team identified novel tumor subclasses and developed biomarkers to allow the stratification of patients. One subclass shows a widespread resistance to current therapies. This is mediated by CYP3A5, which initiates a cascade to inactivate and degrade the drugs. Blockade of CYP3A5 breaks resistance and sensitizes the tumors to these drugs (Nature Medicine 2016).
 

Please register by September 20th, 2016: DKTK-Berlin(at)charite.de
 

We look very much forward to welcoming you to the lecture.

   
Kind regards,
 
Prof. Angelika Eggert                                                    Prof. Carsten Denkert
  

Attendance free
 
 

Downloads

Kontakt

Please Register: DKTK-Berlin(at)charite.de